* Exagen Inc XGN.OQ XGN.O is expected to show a rise in
quarterly revenue when it reports results on November 10.
* The Vista, California-based company is expected to report a
12.6% increase in revenue to $12.134 million from $10.78 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Exagen Inc is for a
loss of 46 cents per share. For the same quarter last year, the
company reported a loss of 34 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Exagen Inc is
$24, about 47.3% above its last closing price of $12.65.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.47 -0.44 -0.38 Beat 13
Mar. 31 2021 -0.47 -0.47 -0.48 Missed -2.3
Dec. 31 2020 -0.38 -0.41 -0.27 Beat 33.4
Sep. 30 2020 -0.47 -0.47 -0.34 Beat 28.4
Jun. -0.75 -0.76 -0.27 Beat 64.4
30 2020
Mar. 31 2020 -0.48 -0.49 -0.44 Beat 10.2
Dec. 31 2019 -0.33 -0.37 -0.27 Beat 26.4
Sep. 30 2019 -2.40 -2.40 -2.30 Beat 4.1
This summary was machine generated November 9 at 03:05 GMT. All
figures in US dollars unless otherwise stated